GSK GlaxoSmithKline PLC

40.19
+0.23  (+1%)
Previous Close 39.96
Open 40.21
Price To Book 22.97
Market Cap 100,242,375,939
Shares 2,494,211,892
Volume 1,366,910
Short Ratio 2.39
Av. Daily Volume 2,411,889

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 1H 2018.
TSR-042
First-line ovarian cancer
FDA Approval announced July 23, 2018.
Tafenoquine
Malaria
Approval announced April 24, 2018 for expanded label.
Trelegy Ellipta (FF/UMEC/VI)
Chronic obstructive pulmonary disease (COPD)
Phase 3 data released September 20, 2017 - primary endpoint met.
Closed Triple - IMPACT
COPD
Approval announced December 12, 2017.
Mepolizumab
Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Phase 3 data due 2H 2019.
Mepolizumab
Severe hypereosinophilic syndrome (HES)
Phase 1/2 trial ongoing. Data at ASCO 2018 noted ORR 25%.
Niraparib and Keytruda (TOPACIO)
Triple-negative Breast Cancer or Ovarian Cancer
Approval announced January 11, 2018.
Fluarix Quadrivalent (Influenza Vaccine)
Influenza A - children 6-35 months of age.
Phase 3 data released July 15, 2019 met primary endpoint.
Niraparib - PRIMA
First-line ovarian cancer
Approval announced September 18, 2017.
Trelegy Ellipta (FF/UMEC/VI)
Chronic obstructive pulmonary disease (COPD)
Approval announced November 21, 2017.
Dolutegravir + rilpivirine
HIV
Advisory Committee July 25, 2018 voted 3-16 against recommending approval. CRL issued September 7, 2018.
Mepolizumab
Chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype
FDA approval announced April 8, 2019.
Dolutegravir + lamivudine
HIV
Phase 3 data due 2H 2020.
Daprodustat - ASCEND-D
Anemia
Phase 3 data due 2H 2020.
Cabotegravir
HIV
Development discontinued due to lack of efficacy.
Danirixin
Chronic obstructive pulmonary disease (COPD)
Approval announced October 20, 2017.
Shingrix
Shingles
Approval announced July 21, 2017.
Benlysta (belimumab) - subcutaneous
Systemic lupus erythematosus (SLE)
Phase 3 data released May 2, 2019 met primary but missed key secondary endpoint.
Closed Triple - CAPTAIN
Asthma
Approval announced September 19, 2017.
Closed Triple
COPD
CRL January 11 2017. FDA Approval announced October 25, 2017 following resubmission.
Rolapitant - intravenous (IV)
Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients
Phase 3 trial no longer be expected to serve as a registration trial - noted March 27, 2017.
Niraparib - BRAVO
Cancer - breast
PDUFA date under priority review was June 30, 2017. Approved March 27, 2017.
Niraparib - NOVA (Niraparib Ovarian)
Cancer - ovarian
PDUFA date under priority review 24 October 2019.
Niraparib - (QUADRA trial)
Ovarian cancer
Approved September 2, 2015.
Rolapitant
Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients
Phase 1 pivotal data and BLA filing due 2H 2019.
TSR-042 - GARNET
Endometrial cancer
NDA filing announced April 29, 2019. Estimated PDUFA date April 28, 2020.
Dolutegravir + rilpivirine
Injectable 2DR in HIV
Phase 3 data due 2H 2020.
Benlysta (belimumab) and rituximab
Systemic lupus erythematosus (SLE)
Phase 3 ContRAst trial initiation announced July 3, 2019.
Otilimab (MOR103/GSK3196165)
Rheumatoid Arthritis
Phase 1 data at SITC Novemeber 2018 - 15% ORR for high dose , 9% ORR for lower dose.
TSR-022 + TSR-042 AMBER
Solid tumors
Phase 2 data due 2H 2019.
Niraparib + bevacizumab OVARIO
Ovarian cancer
Phase 1 trial ongoing.
TSR-033 - CITRINO
Solid tumors
Phase 3 data due 1H 2020.
Mepolizumab - SYNAPSE
Nasal polyps
Phase 3 data due 2H 2019.
GSK’916 - belantamab mafodotin (BCMA)
Multiple myeloma
FDA Approval announced June 6, 2019.
Mepolizumab
Severe eosinophilic asthma - pediatric
Phase 2 initial data to be presented at ASCO GU February 14, 2019. ORR 40%.
Niraparib (Galahad)
Castration-Resistant Prostate Cancer
Phase 3 trial met primary endpoint - June 14, 2018. 96-week data presented July 24, 2019.
Dolutegravir + lamivudine (GEMINI 2)
Phase 3 trial met primary endpoint - June 14, 2018. 96-week data due 3Q 2019.
Phase 3 8-week data due 3Q 2019.
Cabotegravir + rilpivirine - ATLAS2M
HIV
Phase 3 data released July 10, 2019 met primary endpoint.
Dolutegravir + lamivudine TANGO
HIV

Latest News

  1. Ionis Pharmaceuticals Looks to Partners to Pay the Bills
  2. Germany's Stada is "very selective" on acquisitions, CEO says
  3. Should Value Investors Consider GlaxoSmithKline (GSK) Stock?
  4. GSK's new pharma president carries Merck, Pfizer experience
  5. AnaptysBio Prepares for a Potential Gear Shift
  6. Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat
  7. Merck KGaA's Q2 profit bolstered by drug milestone payments
  8. Kahn Brothers' Top 6 Buys in the 2nd Quarter
  9. Local companies impacted by trade war-fueled stock market decline
  10. It Might Be Better To Avoid GlaxoSmithKline plc's (LON:GSK) Upcoming 1.1% Dividend
  11. Edited Transcript of GSK.L earnings conference call or presentation 24-Jul-19 1:00pm GMT
  12. Emergent (EBS) Earnings Miss in Q2, Revenues Beat Estimates
  13. Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger
  14. Theravance (TBPH) Q2 Loss Narrower, Revenues Beat Estimates
  15. GSK, Pfizer complete deal to combine consumer health brands
  16. The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings
  17. Gilead (GILD) Q2 Earnings & Sales Beat, Sales Guidance Raised
  18. Mylan (MYL) Beats on Q2 Earnings, Inks Deal with Pfizer
  19. Pharmacia Corporation (Old Monsanto) -- Moody's reviews Pfizer's A1 rating for downgrade; affirms P-1 rating
  20. Top 5 Dividend Stocks in the FTSE for 2018